Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice

Current Medical Research and Opinion
Steven K HildemannChristoph Bode

Abstract

In order to reduce individual cardiovascular risk, many patients require life-long lipid-lowering therapy, often as a drug combination approach. We aimed to describe the usage pattern, effectiveness and tolerability of long-term treatment with lipid-lowering agents, with particular focus on an oral combination of simvastatin (SIM 10, 20, 40 or 80 mg) plus ezetimibe (EZ 10 mg). A prospective, observational study in 512 general practices throughout Germany. From a sample of patients at moderate or high cardiovascular risk who had previously taken part in a half-year study of an SIM/EZ combination, 5485 patients were documented after 1 year of treatment (mean 58 +/- 16 weeks) with regard to lipid parameters, adverse drug reactions (ADRs) and adverse events. At the start of follow-up, 78.6% of patients were still on the SIM/EZ combination. At the end of follow-up, mean low density lipoprotein cholesterol (LDL-C) in patients on the combination versus those on other lipid-lowering therapy was reduced by 29.3 vs. 17.6% compared with baseline, total cholesterol by 23.1 vs. 14.5%, mean high density lipoprotein cholesterol (HDL-C) was increased by 15.9 vs. 13.4%, and mean triglycerides were reduced by 16.1 vs. 7.9%. Individual LDL-C targ...Continue Reading

References

Jun 22, 2000·The New England Journal of Medicine·J ConcatoR I Horwitz
Nov 10, 2000·Lancet·I R Edwards, J K Aronson
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 6, 2004·American Journal of Therapeutics·James M McKenney
Jun 3, 2004·Annals of Internal Medicine·Andreas Laupacis, Muhammad Mamdani
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Oct 8, 2004·European Journal of Epidemiology·Vicki KristmanPierre Côté
Feb 16, 2005·Expert Opinion on Pharmacotherapy·Peter P Toth, Michael H Davidson
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Apr 1, 2006·Current Medical Research and Opinion·Stella S Daskalopoulou, Dimitri P Mikhailidis
Jul 31, 2007·Current Medical Research and Opinion·D P MikhailidisA L Catapano
Apr 1, 2008·The New England Journal of Medicine·Cynthia A JackeviciusHarlan M Krumholz
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Apr 1, 2008·The New England Journal of Medicine·Jeffrey M DrazenGregory D Curfman
May 7, 2008·Current Medical Research and Opinion·Steven HildemannChristoph Bode
Dec 23, 2008·Medizinische Klinik·Marc-Alexander OhlowBernward Lauer
Jan 24, 2009·Medizinische Klinik·Christa ClaesJohann-Matthias Graf von der Schulenburg

❮ Previous
Next ❯

Citations

Oct 22, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Anselm K GittKurt Bestehorn
Apr 2, 2011·Expert Review of Cardiovascular Therapy·Nkechinyere Ijioma, Jennifer G Robinson
Jan 10, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Karen C ChungMartin Zagari

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.